Exagen Q3 2021 revenue $12.3M (+14% YoY); net loss widens to $7.2M; reaffirms FY guidance

EXAGEN INC.

2021-Q3 EPS reported -$1.27 revenue$35,610,000

Total revenue $12.3M, up 14% YoY; AVISE CTD revenue $9.9M (+34% YoY) on 31,742 tests (+21%).
Net loss of $7.2M vs. $4.3M a year ago; operating expenses rose to $18.8M from $14.6M.
Record 1,969 ordering HCPs and 714 adopters; sequential quarterly retention ~99%.
Signed agreement with Inland Empire Health Plan; in-network lives now ~68.9M.
Entered pilot to supply AVISE MTX to retail pharmacy chain & major payor partnership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.